{"nctId":"NCT02394028","briefTitle":"A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease","startDateStruct":{"date":"2015-03-20","type":"ACTUAL"},"conditions":["Crohn Disease"],"count":1035,"armGroups":[{"label":"Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab","Drug: Placebo"]},{"label":"Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab","Drug: Placebo"]},{"label":"Induction Phase - Cohort 1 (Exploratory): Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab","Drug: Placebo"]},{"label":"Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab","Drug: Placebo"]},{"label":"Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab","Drug: Placebo"]},{"label":"Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab","Drug: Placebo"]},{"label":"Induction Phase - Cohort 3 (Pivotal): Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Maintenance Phase - Placebo Responders: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Maintenance Phase - Etrolizumab Responders: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrolizumab"]}],"interventions":[{"name":"Etrolizumab","otherNames":["RO5490261","RG7413"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Moderately to severely active Crohn's Disease (CD) as determined by the CDAI, patient reported outcomes and endoscopically defined disease activity in the ileum and/or colon\n* Intolerance, refractory disease, or no response to corticosteroids (CS), immunosuppressants (IS), or anti-TNF therapy within 5 years from screening. Participants who have not previously demonstrated inadequate response or intolerance to one or more anti-TNF therapies are eligible to participate in the study provided they are intolerant or refractory to CS or IS therapy\n* Use of effective contraception as defined by the protocol\n\nExclusion Criteria:\n\n* A history of, or current conditions affecting the digestive tract, such as ulcerative colitis, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome\n* Planned surgery for CD\n* Ileostomy or colostomy\n* Has received non-permitted inflammatory bowel disease (IBD) therapies (including natalizumab, vedolizumab, and efalizumab, as stated in the protocol)\n* Any prior treatment with ustekinumab within 14 weeks prior to randomization\n* Chronic hepatitis B or C infection, human immunodeficiency virus (HIV), active or latent tuberculosis (participants with prior history of Bacillus Calmette-Guérin \\[BCG\\] vaccination must pass protocol-defined screening criteria)\n* Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical judgment of the investigator. Fistulas related to CD are not exclusionary\n* Any prior treatment with anti-adhesion molecules (e.g., anti-mucosal addressin cell adhesion molecule \\[anti-MAdCAM-1\\])\n* Any major episode of infection requiring treatment with intravenous antibiotics ≤8 weeks prior to screening or oral antibiotics ≤4 weeks prior to screening. Treatment with antibiotics as adjunctive therapy for CD in the absence of documented infection is not exclusionary\n* Hospitalization (other than for elective reasons) within 4 weeks prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 14","description":"Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal (≤)3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"20.00","spread":null},{"groupId":"OG002","value":"27.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Induction Phase: Cohort 2 and 3: Percentage of Participants With Clinical Remission at Week 14","description":"Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal (≤)3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"29.5","spread":null},{"groupId":"OG004","value":"29.3","spread":null},{"groupId":"OG005","value":"29.2","spread":null},{"groupId":"OG006","value":"30.1","spread":null},{"groupId":"OG007","value":"33.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Induction Phase: Cohort 1: Percentage of Participants With Endoscopic Improvement at Week 14","description":"Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn's Disease (SES-CD) score.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"19.5","spread":null},{"groupId":"OG002","value":"16.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Induction Phase: Cohort 2 and 3: Percentage of Participants With Endoscopic Improvement at Week 14","description":"Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn's Disease (SES-CD) score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"20.8","spread":null},{"groupId":"OG004","value":"22.2","spread":null},{"groupId":"OG005","value":"21.6","spread":null},{"groupId":"OG006","value":"26.2","spread":null},{"groupId":"OG007","value":"27.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Phase: Percentage of Participants With Clinical Remission at Week 66","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.\n\nMaintenance phase participants were evaluated.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"24.00","spread":null},{"groupId":"OG010","value":"35.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Phase: Percentage of Participants With Endoscopic Improvement at Week 66","description":"Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. Maintenance phase participants were evaluated.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"12.2","spread":null},{"groupId":"OG010","value":"23.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 6","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"15.0","spread":null},{"groupId":"OG002","value":"24.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Cohort 2 and 3: Percentage of Participants With Clinical Remission at Week 6","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"20.5","spread":null},{"groupId":"OG004","value":"21.3","spread":null},{"groupId":"OG005","value":"20.8","spread":null},{"groupId":"OG006","value":"23.8","spread":null},{"groupId":"OG007","value":"23.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Cohort 1: Percentage of Participants With SES-CD Score ≤4 (≤2 for Ileal Participants), With No Segment Having a Subcategory Score Greater Than (>)1, at Week 14","description":"Endoscopic Remission is defined as SES-CD total score \\<=4 (\\<=2 for ileal only patients), with no segment having a subcategory score \\>1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"13.8","spread":null},{"groupId":"OG002","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Cohort 2 and 3: Percentage of Participants With SES-CD Score ≤4 (≤2 for Ileal Participants), With No Segment Having a Subcategory Score Greater Than (>)1, at Week 14","description":"Endoscopic Remission is defined as SES-CD total score \\<=4 (\\<=2 for ileal only patients), with no segment having a subcategory score \\>1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"9.9","spread":null},{"groupId":"OG004","value":"12.3","spread":null},{"groupId":"OG005","value":"8.7","spread":null},{"groupId":"OG006","value":"10.2","spread":null},{"groupId":"OG007","value":"15.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Cohort 1: Change From Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14","description":"CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.4"},{"groupId":"OG001","value":"-1.4","spread":"0.3"},{"groupId":"OG002","value":"-1.6","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.4"},{"groupId":"OG001","value":"-1.5","spread":"0.3"},{"groupId":"OG002","value":"-1.3","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Cohort 2 and 3: Change From Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14","description":"CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"-2.0","spread":"0.2"},{"groupId":"OG004","value":"-2.3","spread":"0.2"},{"groupId":"OG005","value":"-1.9","spread":"0.3"},{"groupId":"OG006","value":"-1.6","spread":"0.2"},{"groupId":"OG007","value":"-1.9","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"-2.3","spread":"0.3"},{"groupId":"OG004","value":"-2.2","spread":"0.3"},{"groupId":"OG005","value":"-2.0","spread":"0.3"},{"groupId":"OG006","value":"-2.0","spread":"0.3"},{"groupId":"OG007","value":"-2.3","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Clinical Remission at Week 66, Among Those Who Achieved Clinical Remission at Week 14","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.\n\nInduction Phase Cohorts are not included","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"39.2","spread":null},{"groupId":"OG010","value":"56.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 66, Among Those Who Were Receiving Corticosteroids at Baseline","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.\n\nInduction Phase Cohorts are not included","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"11.0","spread":null},{"groupId":"OG010","value":"29.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Endoscopic Improvement at Week 66 Among Participants Who Achieved Endoscopic Improvement at Week 14","description":"Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. Induction Phase Cohorts are not included","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"25.3","spread":null},{"groupId":"OG010","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With SES-CD Score ≤4 (≤2 for Ileal Participants), With No Segment Having a Subcategory Score >1, at Week 66","description":"Endoscopic Remission is defined as SES-CD total score \\<=4 (\\<=2 for ileal only patients), with no segment having a subcategory score \\>1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"5.9","spread":null},{"groupId":"OG010","value":"12.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Durable Clinical Remission","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Durable clinical remission was defined as clinical remission at ≥4 of the 6 in-clinic assessment visits conducted during the Maintenance Phase at Weeks 24, 28, 32, 44, 56, and 66. Induction Phase Cohorts are not included","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"19.8","spread":null},{"groupId":"OG010","value":"30.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those Who Were Receiving Corticosteroids at Baseline","description":"Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Percentage of participants with clinical remission who will be off corticosteroids for at least 24 weeks prior to Week 66 will be reported.\n\nInduction Phase Cohorts are not included","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"9.9","spread":null},{"groupId":"OG010","value":"25.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Change From Baseline in CD-PRO/SS Score at Week 66","description":"CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG009","value":"-1.7","spread":"0.3"},{"groupId":"OG010","value":"-2.0","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG009","value":"-1.4","spread":"0.2"},{"groupId":"OG010","value":"-1.7","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)","description":"Investigator text for AEs is coded using MedDRA version 24.0. For participants counts, multiple occurrences of AEs in the same category for an individual are counted only once. For event counts, multiple occurrences of AEs in the same category for an individual are counted separately. Severity Grades from 1 to 5.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"82","spread":null},{"groupId":"OG003","value":"120","spread":null},{"groupId":"OG004","value":"115","spread":null},{"groupId":"OG005","value":"51","spread":null},{"groupId":"OG006","value":"95","spread":null},{"groupId":"OG007","value":"85","spread":null},{"groupId":"OG008","value":"42","spread":null},{"groupId":"OG009","value":"190","spread":null},{"groupId":"OG010","value":"189","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants With Adverse Events Leading to Study Drug Discontinuation","description":"Number of participants who discontinued the study due to the adverse events is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"1","spread":null},{"groupId":"OG009","value":"1","spread":null},{"groupId":"OG010","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0","description":"Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0 are reported. Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = Death. The terms 'severe' and 'serious' are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs are counted only once per participant at the highest (worst) grade. Infections are identified by Primary System Organ Class term 'Infections and Infestations'","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"38","spread":null},{"groupId":"OG004","value":"21","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"25","spread":null},{"groupId":"OG007","value":"21","spread":null},{"groupId":"OG008","value":"9","spread":null},{"groupId":"OG009","value":"44","spread":null},{"groupId":"OG010","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"23","spread":null},{"groupId":"OG004","value":"20","spread":null},{"groupId":"OG005","value":"7","spread":null},{"groupId":"OG006","value":"12","spread":null},{"groupId":"OG007","value":"20","spread":null},{"groupId":"OG008","value":"11","spread":null},{"groupId":"OG009","value":"65","spread":null},{"groupId":"OG010","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"2","spread":null},{"groupId":"OG009","value":"11","spread":null},{"groupId":"OG010","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"1","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Experienced at Least One Infection-Related Serious Adverse Event","description":"Investigator text for AEs is coded using MedDRA version 24.0. Infections are identified by primary System Organ Class term 'Infections and Infestations'. The terms 'severe' and 'serious' are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs in the same category for an individual are counted only once","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"2","spread":null},{"groupId":"OG008","value":"1","spread":null},{"groupId":"OG009","value":"13","spread":null},{"groupId":"OG010","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Experienced at Least One Injection-Site Reaction by Severity, According to NCI-CTCAE v4.0","description":"Investigator test for AEs is coding using MedDRA version 24.0. Injection-Site Reactions are identified by eCRF checkbox for local injection site reactions, and/or primary or secondary HLT Injection Site Reactions. Multiple occurrences of AEs for an individual are counted only once, under the worst grade reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"6","spread":null},{"groupId":"OG008","value":"3","spread":null},{"groupId":"OG009","value":"18","spread":null},{"groupId":"OG010","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Experienced at Least One Hypersensitivity Reaction by Severity, According to NCI-CTCAE v4.0","description":"Investigator text for AEs is coded using MedDRA version 24.0. Multiple occurrences of AEs for an individual are counted only once, under the worst grade reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Number of Participants Who Develop Malignancies","description":"Participants with malignancies are reported. 'Malignancies are identified by SMQ Malignant and unspecified tumors (narrow)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"2","spread":null},{"groupId":"OG010","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab","description":"Participants who received at least one dose of study treatment and had at least one baseline or post-baseline ATA result. Induction: treatment groups were pooled across cohorts 1-3. Maintenance: treatment group is stratified by induction dose","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"5.6","spread":null},{"groupId":"OG004","value":"2.8","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22.7","spread":null},{"groupId":"OG002","value":"23.1","spread":null},{"groupId":"OG003","value":"33.9","spread":null},{"groupId":"OG004","value":"33.9","spread":null},{"groupId":"OG005","value":"21.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Trough Serum Concentration (Ctrough) of Etrolizumab","description":"Serum Etrolizumab Trough Concentration","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.39","spread":"4.59"},{"groupId":"OG001","value":"25.1","spread":"11.6"},{"groupId":"OG002","value":"10.3","spread":"5.07"},{"groupId":"OG003","value":"25.7","spread":"11.9"},{"groupId":"OG004","value":"9.78","spread":"4.63"},{"groupId":"OG005","value":"25.5","spread":"11.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"5.27"},{"groupId":"OG001","value":"23.2","spread":"10.6"},{"groupId":"OG002","value":"11.0","spread":"5.04"},{"groupId":"OG003","value":"24.1","spread":"11.4"},{"groupId":"OG004","value":"10.8","spread":"5.43"},{"groupId":"OG005","value":"24.6","spread":"9.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG006","value":"6.15","spread":"4.20"},{"groupId":"OG007","value":"14.8","spread":"10.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG006","value":"6.58","spread":"4.59"},{"groupId":"OG007","value":"8.20","spread":"6.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG006","value":"7.29","spread":"8.45"},{"groupId":"OG007","value":"8.07","spread":"5.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG006","value":"7.13","spread":"9.76"},{"groupId":"OG007","value":"7.89","spread":"5.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG006","value":"6.68","spread":"3.75"},{"groupId":"OG007","value":"8.31","spread":"6.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG006","value":"11.7","spread":"5.82"},{"groupId":"OG007","value":"12.2","spread":"6.44"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":59},"commonTop":["Crohn's disease","Headache","Abdominal pain","Arthralgia","Nasopharyngitis"]}}}